COMMODORE CAPITAL LP - Significant Ownership

Signature - Title
Michael Kramarz - Managing Partner
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by COMMODORE CAPITAL LP.

Significant Ownership of COMMODORE CAPITAL LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CRDF Cardiff Oncology, Inc. Common Stock, $0.0001 par value 8.1% $16.9M 5.38M COMMODORE CAPITAL LP Dec 10, 2024
SLDB Solid Biosciences Inc. Common Stock $0.001 par value per share 7.6% $32.7M 5.83M COMMODORE CAPITAL LP Feb 18, 2025
DRUG Bright Minds Biosciences Inc. Common Shares, without par value 7.2% $18.3M 500K COMMODORE CAPITAL LP Dec 31, 2024
MRUS Merus N.V. Common shares, (euro) 0.09 nominal value per share 5.5% $158M 3.75M Commodore Capital LP Dec 9, 2024
VRDN Viridian Therapeutics, Inc. Common Stock, $0.01 par value per share 5.3% $69.2M 4.3M Commodore Capital LP Apr 4, 2025
NRIX Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share 5.1% $45.7M 3.85M COMMODORE CAPITAL LP Feb 7, 2025
CLDX Celldex Therapeutics, Inc. Common Stock, par value $.001 5% $70.9M 3.35M COMMODORE CAPITAL LP Apr 3, 2025
CELC Celcuity Inc. Common Stock, $0.001 par value per share 2.9% $11M 1.1M COMMODORE CAPITAL LP Dec 31, 2024
NKTX Nkarta, Inc. Common Stock, $0.0001 par value per share 0.5% $633K 352K COMMODORE CAPITAL LP Dec 31, 2024

Schedules 13D/G Reported by COMMODORE CAPITAL LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.